Side effects of novel drugs and managing patient expectations in CLL
Interim results of pegylated interferon alpha-2a for polycythemia vera and essential thrombocythemia
What is the role of allogeneic stem cell transplantation in CLL in the light of novel drugs?
Pros and cons of CML first-line therapy
The multi-cohort SCHOLAR-1 study of refractory aggressive DLBCL